Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas

Rhea-AI Summary

Insilico Medicine has announced a strategic R&D collaboration with Arvinas (NASDAQ: ARVN), focusing on integrating artificial intelligence with PROTAC technology for drug development. This partnership aims to design innovative treatment modalities for various targets, leveraging AI's potential in drug discovery. Insilico has also recently completed a $255 million funding round and nominated its second preclinical candidate for kidney fibrosis. This collaboration signifies a pivotal move in the biotech sector, enhancing the capabilities of both companies in developing transformative therapeutics.

Positive

• Strategic collaboration with Arvinas for AI-augmented PROTAC technology.
• Recent completion of a $255 million funding round, indicating strong investor confidence.
• Nominated second preclinical candidate for kidney fibrosis, expanding product pipeline.

Negative

• None.

HONG KONG, Aug. 9, 2021 /PRNewswire/ -- Insilico Medicine is proud to announce an R&D collaboration with Arvinas (NASDAQ: ARVN). This strategic partnership will involve Insilico Medicine's AI-augmented platforms and close cooperation between Arvinas' and Insilico Medicine's scientists on novel PROTACs. The collaboration will include the design of transformative treatment modalities for existing and next-generation targets; and demonstrate the impact of combining AI with one of the most significant breakthrough technologies in drug discovery - PROTACs.

"Arvinas is the pioneer of PROTAC technology and a leader in protein degradation therapeutics. We look forward to collaborating with Arvinas in this innovative field and to building a lasting relationship," said Alex Zhavoronkov Ph.D., CEO of Insilico Medicine.

In July the company announced the completion of a $255 million round led by Warburg Pincus and joined by over 25 high-profile investors, and in August,  it nominated the second preclinical candidate for kidney fibrosis.

About Insilico Medicine

Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms. These platforms use deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and ageing-related diseases. Since its inception, Insilico Medicine has raised over $300 million from reputable financial, biotechnology, and information technology investors.

Website http://insilico.com/

Media Contact

For further information, images, or interviews, please contact pr@insilico.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insilico-medicine-announces-an-ai-driven-protac-rd-collaboration-with-arvinas-301351106.html

SOURCE Insilico Medicine

FAQ

What is the collaboration between Insilico Medicine and Arvinas about?

Insilico Medicine and Arvinas are collaborating on R&D to combine AI with PROTAC technology for novel drug development.

When was the collaboration between Arvinas and Insilico Medicine announced?

The collaboration was announced on August 9, 2021.

What are PROTACs and why are they significant in drug discovery?

PROTACs are a breakthrough technology in drug discovery that target and degrade specific proteins, allowing for innovative treatment modalities.

How much funding did Insilico Medicine raise recently?

Insilico Medicine recently completed a $255 million funding round led by Warburg Pincus.

What recent progress has Insilico Medicine made in its drug development pipeline?

Insilico Medicine has nominated its second preclinical candidate for kidney fibrosis as part of its ongoing drug development efforts.